Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
Recruiting · Phase 1, Phase 2 · NCT06878560
Conditions: ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
At a glance
- Research payments reported, 2025
- $504,246
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- United Therapeutics
- Tested
- 10 GE Xenokidney (biological)
- Dates
- Started 2025-10-29; completion 2075-10
- Results posted
- Not yet
The purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, 10 GE Xenokidney survival, and screening for zoonotic infec…
From ClinicalTrials.gov, last updated 2026-03-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
United Therapeutics Corporation reported $504,246 in research payments for this study in 2025 (48 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- NYU Grossman School of Medicine $418,883
- $85,363
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.